Eli Lilly and Co. has reached an agreement with pharmaceutical Cipla to market tirzepatide, the active ingredient in Lilly’s ...
Indian drugmaker Cipla Limited has entered into a strategic marketing and distribution agreement with US pharma major Eli ...
The company is banking on key new launches, including weight loss drug Semaglutide and biosimilar Abatacept to drive growth ...
Analysts believe that while the deal is positive, Cipla's share price is unlikely to see a fresh run-up, given the rise it ...
Why is the Supreme Court’s directive to notify a new Saranda wildlife sanctuary important for your UPSC exam? What ...
Capital Market on MSN
Cipla partners with Eli Lilly to distribute Tirzepatide in India under second brand Yurpeak
Mumbai, Oct. 24 -- "The introduction of a second brand of Tirzepatide in India through our commercial agreement with Cipla ...
Cipla, HUL, Kotak Mahindra Bank, Max Healthcare, UltraTech Cement were among top losers on the Nifty, while gainers were Hindalco, Bharti Airtel, Shriram Finance, ICICI Bank. On the sectoral front, ...
The cornerstone of this strategic offensive is the drug Tirzepatide, a compound already achieving blockbuster status in other global markets for treating Type 2 diabetes and obesity. Under the brand ...
Cipla shares drop 3.7% after Eli Lilly deal, but analysts see strong growth in India's obesity market—learn more about the ...
Cipla, HUL, Adani Ports, Max Healthcare, UltraTech Cement were among top losers on the Nifty, while gainers were Hindalco, ...
Asianet Newsable on MSN
Cipla Shares Fall To Biggest Intra-day Lows In Six Months Despite Eli Lilly Deal For Diabetes Drug
Cipla-Eli Lilly partner to distribute Tirzepatide under the Yurpeak brand in India Tirzepatide is used to manage type 2 ...
On October 23, Lilly and Mumbai-based Cipla announced a joint agreement to distribute and promote tirzepatide under the brand ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback